We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

62 hedge funds and large institutions have $25.6M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 26 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

117% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 12

24% more funds holding

Funds holding: 50 → 62 (+12)

4% more capital invested

Capital invested by funds: $24.6M → $25.6M (+$959K)

Holders
62
Holders Change
+12
Holders Change %
+24%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
26
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SS
Sunbelt Securities
Texas
+$5.62M
2
SCM
Sio Capital Management
New York
+$3.06M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.73M
4
Millennium Management
Millennium Management
New York
+$2.23M
5
Marshall Wace
Marshall Wace
United Kingdom
+$1.46M

Top Sellers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
-$601K
2
Morgan Stanley
Morgan Stanley
New York
-$390K
3
PAM
Panagora Asset Management
Massachusetts
-$322K
4
Walleye Capital
Walleye Capital
New York
-$217K
5
AIM
Alambic Investment Management
California
-$126K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
51
Bank of America
North Carolina
$9K -$49.5K -9,301 -76%
Barclays
52
Barclays
United Kingdom
$9K -$28.1K -5,282 -64%
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$8.47K +$8.66K +1,626 +156%
Deutsche Bank
54
Deutsche Bank
Germany
$8K -$31.6K -5,929 -70%
JP Morgan Chase
55
JP Morgan Chase
New York
$8K -$474 -89 -3%
SO
56
STRS Ohio
Ohio
$8K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$5K -$708 -133 -9%
AIP
58
Ameritas Investment Partners
Nebraska
$3K – – –
Federated Hermes
59
Federated Hermes
Pennsylvania
$2K +$1.76K +330 +148%
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$1K -$2.55K -478 -52%
Daiwa Securities Group
61
Daiwa Securities Group
Japan
$1K +$1.56K +293 New
Walleye Capital
62
Walleye Capital
New York
– -$217K -31,100 Closed
Walleye Trading
63
Walleye Trading
New York
– -$112K -16,000 Closed
ProShare Advisors
64
ProShare Advisors
Maryland
– -$86K -12,300 Closed
TRCT
65
Tower Research Capital (TRC)
New York
– -$58.6K -11,001 -98%
PCM
66
Prelude Capital Management
New York
– -$51K -7,317 Closed
UBS Group
67
UBS Group
Switzerland
– -$32K -4,565 Closed
OSAM
68
O'Shaughnessy Asset Management
Connecticut
– -$20K -2,834 Closed
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
– -$5K -644 Closed
1 2
3

RVLP Hedge Fund Activity: Q1 2020 in Review

62 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2020, worth a combined $25.6M — up 3.9% from $24.6M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RVLP positions and 7 closed out — a net gain of 12 holders — while 26 added to existing stakes and 12 trimmed.

The largest buyer was Sunbelt Securities, opening a new position worth an estimated $5.62M. The largest seller was Oxford Asset Management, cutting an estimated $601K.

  • 62 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2020, up from 50 in Q4 2019.
  • Funds reported $25.6M of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2020, up 3.9% quarter-over-quarter.
  • 19 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2020 and 7 closed out, a net change of +12 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q1 2020 was Sunbelt Securities, an estimated $5.62M added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2020 was Oxford Asset Management, an estimated $601K sold.

Based on aggregated 13F filings for Q1 2020.